

Precision's Deep Expertise in Hematology and Other Critical Modalities

The treatment of hematologic diseases has been rapidly evolving—and precision medicine is fueling some of the greatest innovations. With its ability to home in on the exact biology of heterogenous diseases such as hematologic cancers, precision medicine heralds the end of indiscriminate therapy. In its place are gene-based, targeted therapeutic approaches to deliver the right drug to the right patient at the right time.

Precision for Medicine was founded specifically to make this happen. Discover how we can advance your hematology research.

Delivering the Promise of Precision Medicine in Hematology


Precision has a long history of successful work in hematology trials—conducting multiple studies over 2500 sites with 11,500 patients. We have great expertise in cell and gene therapy, modalities that show increasing promise both for hema-oncology and rare hematology disorders such as sickle cell anemia and beta thalassemia. Most important, although liquid tumors have been notoriously difficult to biopsy, our proprietary technology, ApoStream® has changed that. ApoStream's ability to isolate rare cells—including circulating tumor cells, stem cells, progenitor cells, and differentiated immune cells—generates large quantities of high-quality biomarker data from limited samples.

With at least 35 distinct types of leukemia and 50 types of lymphoma, as well as other devastating hematology disorders, much remains to be done.


Precision stands ready.

Deep Expertise Born of Diverse Hematology Programs

Malignant Hematology Experience by Disease



Hematology Studies by Phase



Combining Science and Technology to Advance Your Hematology Studies

Extensive Expertise in Cell Therapy

While allogenic and autologous cellular-matched, customized, cell-based therapeutics offer great hope, these studies also pose unique challenges. Precision has the expertise to meet them head on.

- Logistical coordination of the product from initial collection through manufacturing and return shipment for infusion provides continual traceability
- Precise site qualification requirements, combined with rigorous processes, tracking systems, and planning documents and thorough site training, leave no room for error
- Our Adoptive Cell Therapy Working Group brings together experts from across Precision to stay at the leading edge of cell therapy study management—from data considerations to the regulatory environment to patient safety

Our Staff's Experience	
Cell Therapy	24%
Leukapheresis	18%
GMO	16%
TCRs Therapy	13%
Personalized Vaccine Study	13%

Proprietary Technology for Liquid Biopsy

Precision offers a suite of liquid biopsy services to capture and enrich circulating tumor cells for downstream characterization.

- Using our proprietary technology, ApoStream®, we are able to isolate target cells using dielectrophoresis field-flow assist—pinpointing rare cells that are fewer than 1 in a billion and capturing them in a viable state
- Harnessing a range of platform technologies, including quantitative image analysis, FISH, ISH, and genomics (including transcriptomics at the single-cell level), we identify cancer type-specific panels for detecting both epithelial and mesenchymal subtypes at any point during therapy

This enables us to help define mechanism of action, inhibition of cell signaling pathways, predictive markers and resistance biomarkers. It also allows us to monitor the pharmacodynamic effects of a therapy at each cycle—critical knowledge on the path to vital new treatments.



To learn more about Precision for Medicine, please contact us at info@precisionformedicine.com, or visit precisionformedicine.com.

